Boston Partners Lowers Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Boston Partners cut its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 28.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 407,984 shares of the biopharmaceutical company's stock after selling 163,963 shares during the period. Boston Partners owned 0.32% of Halozyme Therapeutics worth $19,955,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC purchased a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock valued at $1,754,451 in the last ninety days. Insiders own 2.40% of the company's stock.

Remove Ads

Halozyme Therapeutics Stock Up 1.3 %

Shares of HALO stock traded up $0.82 during trading hours on Tuesday, reaching $64.84. 1,421,761 shares of the stock were exchanged, compared to its average volume of 1,333,866. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00. The business's fifty day moving average is $58.39 and its two-hundred day moving average is $54.68. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The firm has a market capitalization of $8.01 billion, a P/E ratio of 18.90, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on HALO shares. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Benchmark reaffirmed a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.